Literature DB >> 8208938

Healing flare in skeletal metastases from breast cancer.

M J Janicek1, D F Hayes, W D Kaplan.   

Abstract

PURPOSE: To identify the frequency, characteristics, and prognostic significance of scintigraphically detected healing flare in patients with breast cancer metastatic to bone.
MATERIALS AND METHODS: Findings on bone scans and concomitant radiographs of 1,188 patients were reviewed. Bone metastases occurred in 426 patients. Outcomes of 101 patients (aged 21-71 years) with skeletal metastases were correlated with typical scintigraphic and radiographic features.
RESULTS: Healing flare with increased radiotracer uptake and radiographically demonstrated sclerotic changes in osteolytic or mixed skeletal metastases were prospectively identified in 12% of patients with skeletal metastases. Healing flare was detected 3.2 months +/- 1.4 after initiation of hormonal treatment or chemotherapy. Skeletal metastatic activity stabilized on bone scans within 6.2 months +/- 3.0. Patients with healing flare did not survive longer than patients without healing flare but with stable metastases after treatment (3.3 years +/- 2.0 vs 3.9 years +/- 1.6).
CONCLUSION: Scintigraphically detected healing flare represents a favorable response to therapy not associated with increased survival.

Entities:  

Mesh:

Year:  1994        PMID: 8208938     DOI: 10.1148/radiology.192.1.8208938

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  18 in total

1.  Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.

Authors:  Charles J Ryan; Shreya Shah; Eleni Efstathiou; Matthew R Smith; Mary-Ellen Taplin; Glenn J Bubley; Christopher J Logothetis; Thian Kheoh; Christine Kilian; Christopher M Haqq; Arturo Molina; Eric J Small
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy.

Authors:  Connie Y Chang; F Joseph Simeone; Martin Torriani; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2017-06-30       Impact factor: 2.199

3.  False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature.

Authors:  Yi-Shan Yu; Wan-Hu Li; Ming-Huan Li; Xue Meng; L I Kong; Jin-Ming Yu
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

4.  Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide.

Authors:  Jennifer E Sprague; Hideki Kitaura; Wei Zou; Yunpeng Ye; Samuel Achilefu; Katherine N Weilbaecher; Steven L Teitelbaum; Carolyn J Anderson
Journal:  J Nucl Med       Date:  2007-02       Impact factor: 10.057

5.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

6.  Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer.

Authors:  Joerg Stattaus; Steffen Hahn; Thomas Gauler; Wilfried Eberhardt; Stefan P Mueller; Michael Forsting; Susanne C Ladd
Journal:  Eur Radiol       Date:  2008-08-02       Impact factor: 5.315

7.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

Authors:  Colleen M Costelloe; Hubert H Chuang; John E Madewell; Naoto T Ueno
Journal:  J Cancer       Date:  2010-06-28       Impact factor: 4.207

8.  Bone metabolic markers in bone metastases.

Authors:  M Koizumi; Y Yamada; T Takiguchi; E Nomura; M Furukawa; T Kitahara; T Yamashita; H Maeda; S Takahashi; K Aiba
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Flare response versus disease progression in patients with non-small cell lung cancer.

Authors:  Khalsa Al-Nabhani; Rizwan Syed; Athar Haroon; Omar Almukhailed; Jamshed Bomanji
Journal:  J Radiol Case Rep       Date:  2012-11-01

10.  Analysis of clinicopathological factors associated with bone metastasis in breast cancer.

Authors:  Jing Chen; Shu Zhu; Xiu-Zhen Xie; Shan-Feng Guo; Liang-Qian Tong; Sheng Zhou; Ming Zhao; Zhi-Qun Xianyu; Xiao-Hua Zhu; Wei Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.